Navigation Links
CSHL study shows that some malignant tumors can be shut down after all
Date:11/9/2009

Cold Spring Harbor, N.Y. Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated.

These tumors might be tough, but they're not invincible, suggests a new study from Cold Spring Harbor Laboratory (CSHL). The chink in the tumors' armor, according to CSHL Associate Professor Alea Mills, Ph.D., is a protein called TAp63, an older sibling of p53 that's usually intact and not mutated in most cancers.

Mills and her team have succeeded in shutting off the growth of tumors in which p53 is missing by turning up the production of TAp63 proteins, which make up one class of proteins produced by the p63 gene. TAp63 completely blocked tumor initiation, the team found, by inducing senescence, a state of growth arrest in which tumor cells are still metabolically alive but fail to divide. More importantly, turning up the levels of TAp63 in cells that did not have p53 blocked the progression of established tumors in mice.

"We were very excited to see that TAp63 shuts down cancer completely independently of p53," says Mills. "This means that we now have a way of attacking cancers that have damaged p53, which are very difficult to treat in the clinic." The study, funded by a Research Scholar Award from the American Cancer Society, appears online ahead of print on November 8th in Nature Cell Biology.

TAp63 protects from cancer

"p63 is a double-edged sword," says Mills, who discovered it when she was a postdoctoral researcher almost a decade ago. Of the six different proteins that are produced from the p63 gene, three promote activities that could lead to cancer. The remaining three, which are TAp63 versions, do the opposite: prevent cancer by triggering senescencea process th
'/>"/>

Contact: Hema Bashyam
bashyam@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... the genetic instructions inside corn, one of the ... the most complex sequences of DNA ever analyzed, ...vid Schwartz, who was one of more than 100 authors... maize genome is a true maze full of confusing re...quencers for years," says Schwartz. , Publicatio...
(Date:11/19/2009)...-FirstCall/ -- BIO-key International, Inc. (OTC Bu...afety and finger-based biometric identification so...eting held today was adjourned without any action ..., (Logo: http://www.newscom.com/cgi-bin/prnh/2005...f the 35 million votes cast voted in favor of the ...
(Date:11/19/2009)...tified thousands of diverse genes in genetically i... may allow breeders and researchers to use this ge...reate new varieties that were not easily possible ...ience , the researchers, whose senior and first au... of haplotypes sets of closely linked gene varian...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New map of variation in maize genetics holds promise for developing new varieties 2American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 1American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 2American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 3American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 4American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 5American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 6American Heart Association Late Breaking Clinical Trial Report 3A New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint but Di 6268 7Materials Science and Mathematics Research Honored at Nations Premier High School Science Competition 61365 1Materials Science and Mathematics Research Honored at Nations Premier High School Science Competition 61365 2Materials Science and Mathematics Research Honored at Nations Premier High School Science Competition 61365 3Materials Science and Mathematics Research Honored at Nations Premier High School Science Competition 61365 4Materials Science and Mathematics Research Honored at Nations Premier High School Science Competition 61365 5Materials Science and Mathematics Research Honored at Nations Premier High School Science Competition 61365 6In touch with molecules 14836 1In touch with molecules 14836 2
...ancer that are important to treatment can be ident... research team led by scientists at The University...Lancet Oncology online. , Researchers developed an...ntifies whether a tumor,s growth is fueled by the ...actor receptor known as HER-2 that makes a tumor v...
...thod for developing wrinkled hard skins on the sur...y controlling the direction and intensity of the i...ns on flat areas of polydimethylsiloxane, a silico...e primary ingredient in Silly Putty). The techniqu...rofluidic devices and may offer new ways to build ...
... past events like an exciting holiday or a jolly b...in keeps track of the temporal sequence in such me...fter Mary left the party? , Previous findings fro...rsity of Lübeck have confirmed the widely held vie...during sleep, and that this process relies on the ...
Other Biology News:Gene expression test reveals ER and HER-2 status of breast tumors 2Applied scientists create wrinkled 'skin' on polymers 2
(Date:11/19/2009)...rstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), anno...to its shareholders, discussing the Company,s acqu...uticals Holdings, Inc. (CHBP), an integrated bio-p...ic of China. The merger gives NeoStem a controllin...td., CHBP,s primary operating subsidiary and a pro...
(Date:11/19/2009)... Aegera Therapeutics Inc. announced today the dosi...tudy of AEG35156, a targeted antisense therapeutic...dications. ,, The study, entitled "An Open-Labe...or of Apoptosis (XIAP) Antisense AEG35156 Given in...cin in AML Following Failure of a Single Standard ...
(Date:11/19/2009)...r 19 AFFiRiS AG will focus its,Alz...at an unexpectedly early,stage of development: the...hase II clinical trial early in 2010. This decisio...n of two Phase I trials with the candidates,AD01 a...e first interim,analysis of the secondary endpoint...
(Date:11/18/2009)... postage stamp that can sniff out poisonous gases ... reported in the Sept. 13 issue of the journal Na...he University of Illinois have developed an artifi...trial chemicals (TICs) that is simple, fast and in...ensor array could be useful in detecting high expo...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
... Wis. - NimbleGen Systems, a Madison-based manu...ts products sold worldwide as the result of licens...logy , a microarray consultancy service headquarte...supply agreement, the British firm will obtain DN... the molecular level, from NimbleGen for use in it...
...ombom, the retiring vice president and CIO of Mer...ago, when a physician stopped him in the hallway t...d just finished installing its existing phone syst...are your physicians not consulted in the selection...shaped a key process improvement for many informat...
...e, Wis. - Michael J. Dunn , who has served as ex...llege of Wisconsin for the past 12 years, has ann...til a successor is named. , ,Dunn, 70, will becom...,s Department of Medicine once a replacement is fo... the Medical College, said the institution will be...
Other Biology Technology:CIO Leadership Series: Peter Strombom, Meriter Hospital 2CIO Leadership Series: Peter Strombom, Meriter Hospital 3CIO Leadership Series: Peter Strombom, Meriter Hospital 4
Anti-Bunyavirus (G1) Monoclonal Antibody, Unconjugated, Clone 8C2.1 from CHEMICON
Rabbit Anti-BI-1 Polyclonal Antibody, Unconjugated from BioVision
Capped Xef-1 RNA 0.05 ml from Ambion
Human TIMP-1 ELISpot Kit from R&D Systems
Biology Products: